Everything you need to know as a first-time student.
Information and support for postgraduate study.
Courses, supervisors and your life as a researcher.
Step-by-step application guides for our courses.
Get financial support for your studies. Find a scholarship that's right for you.
Options like part-time, external and online study can help you tailor how you learn.
Boost your career or extend your skills with a short course or unit.
Our free online courses are open to everyone.
Discover our campuses, courses and entry requirements.
Our internationally recognised research is supported by state-of-the-art research infrastructure.
Considering research with us? Here's what to expect.
PhDs, research masters and professional doctorates.
Apply for scholarships for research study, or competitive grants as a professional researcher.
Our researchers work in supportive and established networks.
We value and promote integrity and ethical responsibility in all research we conduct.
Our strengths and areas of focus in research.
Browse our experts or find a supervisor.
We collaborate with industry partners to research solutions for real-world problems, and to give our students hands-on experience in the workplace.
Work with our students and graduates, sponsor scholarships, prizes or events, or become an industry partner.
We offer commercial research and consultancy services, research commercialisation, and workplace training and development.
We offer short courses to help you advance your career and expand your skills.
We're working with a range of industry partners and collaborators.
Boeing Australia have collaborated on projects with us and provided sponsorship, and their staff have taught in our avionics program.
We are a highly successful and globally positioned Australian university with an applied emphasis in courses and research.
Make a real impact by giving to QUT and supporting our students, researchers and community.
Our history, key statistics, sustainability initiatives and programs and Indigenous acknowledgement.
Meet our staff and executive team.
Our awards, accreditation details, research rankings and scholarly achievements.
Our plans for expanding our university's achievements in learning, teaching and research.
Policies, procedures and annual reports.
What's on at QUT.
Want to work with us? See available jobs.
Our campuses and facilities, including maps, research locations and public venues.
Email: firstname.lastname@example.org Phone: +61 7 3138 2000 Mon-Fri, 8.30am-5pm.
Our graduates run successful businesses, conduct ground-breaking research and make significant contributions to their communities.
We celebrate our alumni with annual awards for graduates and students.
Get involved with QUT by engaging with and supporting our current students.
Once you've graduated, we encourage you to keep in touch with the QUT community and your fellow alumni.
Email: email@example.com Phone: +61 7 3138 4778 Mon-Fri, 8.30am-5pm
Award-winning singer-songwriter and ARIA-nominated artist Kate Miller-Heidke is the 2016 QUT Alumnus of the Year.
Step-by-step guide to applying as an international student.
We offer scholarships for international students to help with study and living costs.
You may be able to meet with a QUT staff member or official representative in your city.
Find out more about living and studying in Brisbane.
While you're studying here, you can access a range of support services to help you adjust to life in Brisbane.
Come to QUT for one or two semesters.
Freecall: 1800 181 848 (within Australia)
Phone: +61 3 9627 4853 (outside Australia)
Subscribe for email updates
Meet the new face of environmental monitoring – a combination of unmanned aerial vehicles (UAV) and a highly specialised camera that was once so big and expensive only satellites and airplanes could carry them.
Email: firstname.lastname@example.org Phone: +61 7 3138 2361
You are here:
Survival rates of the world's most common cancer might soon be increased with a new vitamin E treatment which could significantly reduce tumour regrowth.
Queensland University of Technology (QUT) prostate cancer researchers are leading the fight against a disease which kills 3000 Australian men a year.
Dr Patrick Ling, whose research will be a centrepiece of the new $354 million Translational Research Institute (TRI) when it opens in Brisbane, is leading a team of researchers who have identified a particular constituent of vitamin E, known as tocotrienol (T3), which can inhibit the growth of prostate tumours.
Construction of TRI officially began today (October 19) at the Princess Alexandra Hospital. The world-class facility brings together some of Queensland's best medical researchers from four leading Australian research facilities to turn their work into accessible and potentially life-saving health treatments.
Dr Ling's research has been funded by Davos Life Science in Singapore, who recently awarded him a further $128,000 to undertake a one-year study of the long-term effectiveness of T3 to prevent the recurrence of treated prostate cancer tumours.
"Prostate cancer is the most common type of cancer in developed countries," Dr Ling said.
"It is responsible for more male deaths than any other cancer, except lung cancer."
Dr Ling said existing chemotherapy and hormonal therapy treatment of prostate cancer was insufficient because it failed to kill off the prostate cancer stem cells (CSCs) which were believed to be responsible for the regrowth of tumours.
However, the research team have discovered a particular form of T3, called gamma-tocotrienol (γ-T3), can successfully kill off the prostate cancer CSCs.
"Currently there is no effective treatment for metastatic prostate cancer, because it grows back after conventional therapies in more than 70 per cent of cases," he said.
"But with γ-T3, QUT researchers have found a better way to treat prostate cancer, which has the potential to inhibit recurrence of the disease."
Dr Ling said in animal trials, γ-T3 completely inhibited tumour formation in more than 70 per cent of the mice implanted with prostate cancer cells and fed the vitamin E constituent in water. In the remaining cases, tumour regrowth was considerably reduced, while tumours reformed in 100 per cent of the control group.
The findings were published recently in the International Journal of Cancer.
The next stage of Dr Ling's study has begun and will determine the long-term effectiveness of the γ-T3 treatment, with plans to progress to clinical trials in the future.
"Previous clinical trials using another vitamin E constituent to inhibit prostate cancer development were unsuccessful, but these trials did not use the vitamin E constituent γ-T3," he said.
"Other research has found γ-T3 is also effective in suppressing other types of cancer, including breast, colon, liver and gastric."
Dr Ling said while not all vitamin E preparations had the active constituent, natural vitamin E obtained from palm oil was rich in γ-T3.
Professor Ross Young, from QUT's Institute of Health and Biomedical Innovation (IHBI), said one of TRI's greatest strengths was to bring together leading researchers.
"Collaboration, which combines the expertise of researchers from different disciplines and institutions to achieve common goals, will lead to better solutions," Professor Young said.
QUT Vice-Chancellor Professor Peter Coaldrake said TRI would greatly benefit Queensland's and Australia's economy and ability to attract the world's best researchers to our shores.
"By having this world-class facility producing research of the highest quality, we will be increasing Queensland's international competitiveness in research," Professor Coaldrake said.
TRI is a collaboration of QUT, the University of Queensland, Princess Alexandra Hospital and the Mater Medical Research Institute, with funding from the Australian Government, Queensland Government, The Atlantic Philanthropies, QUT and UQ.
Dr Ling is based at IHBI and the Australian Prostate Cancer Research Centre - Queensland, a comprehensive research centre to investigate new ways to treat prostate cancer established by QUT and the Princess Alexandra Hospital with funding from the federal government.
His research is funded by world-leading tocotrienol manufacturer Davos Life Science. The Singapore-based company produces γ-T3 from sustainable palm plantations.
Media contact: Rachael Wilson, QUT media officer, 07 3138 1150 or email@example.com.
Dr Patrick Ling